Tyra Biosciences to Present at Upcoming Investor Conferences
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in two major investor conferences. CEO Todd Harris will present at the Jefferies London Healthcare Conference (November 19-21st, 2024) with a fireside chat on November 19th at 2:00 pm GMT, and at the 36th Annual Piper Healthcare Conference (December 3-5th, 2024) in New York with a presentation on December 4th at 10:30 am ET. Management will participate in one-on-one investor meetings at both events. Webcasts will be available on TYRA's website.
Tyra Biosciences (Nasdaq: TYRA), una compagnia biotecnologica in fase clinica specializzata in farmaci di precisione per il recettore del fattore di crescita dei fibroblasti (FGFR), ha annunciato la sua partecipazione a due importanti conferenze per investitori. Il CEO Todd Harris presenterà alla Jefferies London Healthcare Conference (19-21 novembre 2024) con una chiacchierata informale il 19 novembre alle 14:00 GMT, e alla 36a Annual Piper Healthcare Conference (3-5 dicembre 2024) a New York con una presentazione il 4 dicembre alle 10:30 ET. La direzione parteciperà a incontri individuali con gli investitori durante entrambi gli eventi. Le trasmissioni in diretta saranno disponibili sul sito web di TYRA.
Tyra Biosciences (Nasdaq: TYRA), una empresa biotecnológica en etapa clínica especializada en medicamentos de precisión para el receptor del factor de crecimiento de fibroblastos (FGFR), ha anunciado su participación en dos importantes conferencias para inversores. El CEO Todd Harris presentará en la Jefferies London Healthcare Conference (19-21 de noviembre de 2024) con una charla informal el 19 de noviembre a las 14:00 GMT, y en la 36ª Conferencia Anual de Salud Piper (3-5 de diciembre de 2024) en Nueva York con una presentación el 4 de diciembre a las 10:30 ET. La dirección participará en reuniones individuales con inversores en ambos eventos. Las transmisiones estarán disponibles en el sitio web de TYRA.
타이라 바이오사이언스 (Nasdaq: TYRA)는 섬유아세포 성장 인자 수용체(FGFR) 정밀 의약품을 전문으로 하는 임상 단계의 생명공학 회사로, 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. CEO인 토드 해리스(Todd Harris)는 제프리스 런던 헬스케어 컨퍼런스 (2024년 11월 19-21일)에서 11월 19일 오후 2시 GMT에 화로 대담을 진행하고, 제36회 파이퍼 헬스케어 컨퍼런스 (2024년 12월 3-5일)에서 12월 4일 오전 10시 30분 ET에 발표를 할 예정입니다. 경영진은 두 행사에서 개별 투자자와의 미팅에 참석할 것입니다. 웹캐스트는 TYRA의 웹사이트에서 제공될 예정입니다.
Tyra Biosciences (Nasdaq: TYRA), une entreprise de biotechnologie en phase clinique spécialisée dans les médicaments de précision pour les récepteurs du facteur de croissance des fibroblastes (FGFR), a annoncé sa participation à deux grandes conférences pour investisseurs. Le PDG Todd Harris fera une présentation à la Jefferies London Healthcare Conference (19-21 novembre 2024) avec un entretien informel le 19 novembre à 14h00 GMT, et à la 36e Conférence Annuelle Piper Healthcare (3-5 décembre 2024) à New York avec une présentation le 4 décembre à 10h30 ET. La direction participera à des réunions individuelles avec des investisseurs lors des deux événements. Des webdiffusions seront disponibles sur le site web de TYRA.
Tyra Biosciences (Nasdaq: TYRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf Präzisionsmedikamente für den Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR) spezialisiert ist, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen angekündigt. CEO Todd Harris wird auf der Jefferies London Healthcare Conference (19.-21. November 2024) am 19. November um 14:00 Uhr GMT bei einem Gespräch am Feuer präsentieren und auf der 36. jährlichen Piper Healthcare Conference (3.-5. Dezember 2024) in New York am 4. Dezember um 10:30 Uhr ET eine Präsentation halten. Das Management wird an Einzelgesprächen mit Investoren bei beiden Veranstaltungen teilnehmen. Webcasts werden auf der Website von TYRA verfügbar sein.
- None.
- None.
Jefferies London Healthcare Conference, November 19-21st, 2024:
- Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, November 19th, at 2:00 pm GMT.
- TYRA management will also participate in one-on-one investor meetings and B2B meetings.
36th Annual Piper Healthcare Conference, December 3-5th, 2024,
- Mr. Harris will participate in a fireside chat on Wednesday, December 4th, at 10:30 am ET.
- TYRA management will also participate in one-on-one meetings with investors.
A live and archived webcast of the fireside chats will be available via the For Investors page on the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is in development for the treatment of cancer in the SURF301 Phase 1/2 study and for achondroplasia in the BEACH301 Phase 2 study. TYRA is also developing TYRA-200, an investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-302304521.html
SOURCE Tyra Biosciences
FAQ
When will Tyra Biosciences (TYRA) present at the Jefferies London Healthcare Conference 2024?
What conferences will Tyra Biosciences (TYRA) attend in November-December 2024?
Where can investors watch Tyra Biosciences (TYRA) conference presentations?
What time is Tyra Biosciences' (TYRA) presentation at the Piper Healthcare Conference 2024?
